A PROSPECTIVE, PHASE IIA STUDY OF THE EFFECT OF FLUTAMIDE (125 OR 250 MG/DAY) TAKEN FOR 6 WEEKS ON EXPRESSION OF POTENTIAL BIOMARKERS OF FLUTAMIDE ACTION IN THE OVARIES OF WOMEN AT INCREASED RISK FOR OVARIAN CANCER.

Status: Active, no longer recruiting

Phase of Trial: Phase II

Latest Information Update: 18 Sep 2021

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Flutamide (Primary)
Indications Ovarian cancer
Focus Biomarker; Pharmacodynamics

Most Recent Events

24 Jul 2018 Biomarkers information updated
18 Jun 2012 Planned end date changed from 1 Nov 2012 to 1 Feb 2013 as reported by ClinicalTrials.gov.
18 Jun 2012 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com

Welcome to AdisInsight